Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
09 sept. 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments...
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results
08 août 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Quoin Broadens Product Portfolio through Research Agreement with University College Cork, Ireland Company Expands On-going Clinical Trials in Netherton Syndrome to Include International Sites ...
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
06 août 2024 05h00 HE
|
Quoin Pharmaceuticals, Inc.
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
01 août 2024 16h10 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
27 juin 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has...
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25 juin 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
12 juin 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
09 mai 2024 08h30 HE
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
02 mai 2024 16h10 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
13 mars 2024 16h05 HE
|
Quoin Pharmaceuticals, Inc.
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...